PLEASANTON, Calif., Feb. 25 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance
PAD represents a large unmet clinical need and a critical public health issue. Current balloon and stent therapies suffer from shortcomings in the challenging peripheral environment, evidenced by a low rate of acute and long term success.
"The Glider™ PTA 510K clearance is an important step towards sales of our products in the US market," said Eitan Konstantino, Ph.D., President and Chief Executive Officer of TMI. "This product complements our existing portfolio of Glider™ PTCA and Antares® stent system that are approved and sold in Europe."
An advanced and differentiated product for the PAD therapy market, Glider™ PTA catheters have shaft construction reinforced for torque transmission and an a-traumatic tapered tip configuration. Designed to be delivered through the complex peripheral anatomy to cross long and tight lesions and to restore blood flow in the vessels, Glider™ PTA catheters provide physicians a powerful new tool to treat patients with PAD.
About TriReme Medical, Inc.
Based in Pleasanton, California, TriReme Medical, Inc. (TMI) is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The Company's novel balloon and stent therapies are specifically designed for large, unmet clinical needs.
TMI can be contacted at +1 (925) 931-1300 or [email protected].
SOURCE TriReme Medical, Inc.
Subscribe to our Free Newsletters!